Spanish Oncology Genito-Urinary Group
Quick facts
Phase 2 pipeline
- Cetrelimab and Erdafitinib combination
- Erdafitinib monotherapy · Oncology
Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling in cancer cells. - Hormone and radiation therapy
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: